HBV持续感染及其机制的研究进展

陈欢; 杨燕卿; 储君; 张国远; 林世德

doi:10.3969/j.issn.1001-5256.2020.01.041

HBV持续感染及其机制的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.01.041

遵义医科大学附属医院感染科

基金项目:

国家自然科学基金(814600124/H0316)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1052
- HTML全文浏览量: 40
- PDF下载量: 294
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-28
- 出版日期: 2020-01-20

Research advances in persistent hepatitis B virus infection and its mechanism

Department of Infectious Diseases,The Affiliated Hospital of Zunyi Medical University

Research funding:

摘要

摘要: HBV属嗜肝DNA病毒科,可引起人类急性和慢性肝炎,甚至肝硬化、肝癌。目前的抗病毒药物因不能彻底清除肝细胞内HBV,故很难达到治愈的效果。近年来,HBV持续感染的机制受到广泛关注,主要涉及宿主与病毒两方面,从病毒方面展开,主要阐述了cccDNA、HBV颗粒和HBV自身组分维持HBV持续感染的相关研究进展。
- 乙型肝炎病毒 /
- 乙型肝炎表面抗原 /
- 乙型肝炎e抗原 /
- 乙型肝炎核心抗原 /
- DNA,环状
Abstract: Hepatitis B virus(HBV) belongs to the Hepadnaviridae family and can cause acute and chronic hepatitis,liver cirrhosis,and even liver cancer in humans. Current antiviral drugs cannot completely eliminate HBV in liver cells and thus it is difficult to achieve a curative effect. In recent years,the mechanism of persistent HBV infection has attracted wide attention,which mainly involves host and virus. This article elaborates on the research advances in persistent HBV infection from the aspect of virus,including covalently closed circular DNA,HBV particles,and HBV components.
- hepatitis B virus /
- hepatitis B surface antigen /
- hepatitis B e antigen /
- hepatitis B core antigen /
- DNA,circular

HTML全文

参考文献(45)

[1] GBD 2016 Causes of Death Collaborators. Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2017,390(10100):1151-1210.

[2] ALLWEISS L,VOLZ T,GIERSCH K,et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut,2018,67(3):542-552.

[3] YUEN MF,CHEN DS,DUSHEIKO GM,et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers,2018,4:18035.

[4] TONG S,REVILL P. Overview of hepatitis B viral replication and genetic variability[J]. J Hepatol,2016,64(1 Suppl):s4-s16.

[5] YANG HC,CHEN PJ. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA[J]. Virus Res,2018,244:304-310.

[6] LUCIFORA J,PROTZER U. Attacking hepatitis B virus cccDNA———The holy grail to hepatitis B cure[J]. J Hepatol,2016,64(1 Suppl):s41-s48.

[7] DONG J,YING J,QIU X,et al. Advanced strategies for eliminating the cccDNA of HBV[J]. Dig Dis Sci,2018,63(1):7-15.

[8] KO C,CHAKRABORTY A,CHOU WM,et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels[J]. J Hepatol,2018,69(6):1231-1241.

[9] ZHOU L,REN JH,CHENG ST,et al. A functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis B Virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A[J]. Hepatology,2019,69(5):1885-1902.

[10] HENSEL KO,CANTNER F,BANGERT F,et al. Episomal HBV persistence within transcribed host nuclear chromatin compartments involves HBx[J]. Epigenetics Chromatin,2018,11(1):34.

[11] ZHANG Y,HE S,GUO JJ,et al. Retinoid X receptorα-dependent HBV minichromosome remodeling and viral replication[J]. Ann Hepatol,2017,16(4):501-509.

[12] HENSEL KO,RENDON JC,NAVAS MC,et al. Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies[J]. FEBS J,2017,284(21):3550-3572.

[13] ZHANG D,WANG Y,ZHANG HY,et al. Histone deacetylases and acetylated histone H3 are involved in the process of hepatitis B virus DNA replication[J]. Life Sci,2019,223:1-8.

[14] SLAGLE BL,BOUCHARD MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications[J]. Curr Opin Virol,2018,30:32-38.

[15] KINOSHITA W,OGURA N,WATASHI K,et al. Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells[J]. Biochem Biophys Res Commun,2017,482(4):638-644.

[16] CHONG CK,CHENG C,TSOI S,et al. Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome[J]. Antiviral Res,2017,144:1-7.

[17] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.

[18] KARAYIANNIS P. Hepatitis B virus:Virology,molecular biology,life cycle and intrahepatic spread[J]. Hepatol Int,2017,11(6):500-508.

[19] WANG S,CHEN Z,HU C,et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation[J]. J Immunol,2013,190(10):5142-5151.

[20] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462.

[21] BI X,TONG S. Impact of immune escape mutations and Nlinked glycosylation on the secretion of hepatitis B virus virions and subviral particles:Role of the small envelope protein[J].Virology,2018,518:358-368.

[22] EZZIKOURI S,OZAWA M,KOHARA M,et al. Recent insights into hepatitis B virus-host interactions[J]. J Med Virol,2014,86(6):925-932.

[23] WANG T,DAI Y,ZHANG M,et al. Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with lowlevel HBsAg[J]. Int J Mol Med,2018,42(5):2689-2699.

[24] XIANG KH,MICHAILIDIS E,DING H,et al. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion,antigenicity,HBsAg and viral DNA[J]. J Hepatol,2017,66(2):288-296.

[25] HU B,WANG R,FU J,et al. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy[J]. J Gastroenterol Hepatol,2018,33(7):1389-1396.

[26] BIAN Y,ZHANG Z,SUN Z,et al. Vaccines targeting preS1domain overcome immune tolerance in hepatitis B virus carrier mice[J]. Hepatology,2017,66(4):1067-1082.

[27] RUAN L,HADDEN JA,ZLOTNICK A. Assembly properties of hepatitis B virus core protein mutants correlate with their resistance to assembly-directed antivirals[J]. J Virol,2018,92(20). e01082-18.

[28] DIAB A,FOCA A,ZOULIM F,et al. The diverse functions of the hepatitis B core/capsid protein(HBc)in the viral life cycle:Implications for the development of HBc-targeting antivirals[J]. Antiviral Res,2018,149:211-220.

[29] FERNNDEZ M,QUIROGA JA,CARREO V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins[J]. J Gen Virol,2003,84(Pt8):2073-2082.

[30] DU J,LIANG X,LIU Y,et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression[J]. Cell Death Differ,2009,16(2):219-229.

[31] LI M,ZHOU ZH,SUN XH,et al. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway:A possible mechanism of hepatitis B virus persistence[J]. Lab Invest,2016,96(11):1156-1164.

[32] LIU L,HUANG Y,ZHANG K,et al. Hepatitis B core antigen regulates dendritic cell proliferation and apoptosis through regulation of PKC/NF-κB signaling pathway[J]. Mol Med Rep,2018,18(6):5726-5732.

[33] YAN Z,WU D,HU H,et al. Direct inhibition of hepatitis B e antigen by core protein allosteric modulator[J]. Hepatology,2019,70(1):11-24.

[34] ZOU HX,WANG JH,CUI HL,et al. The relativity study between abnormal serum markers of hepatitis B and HBV-DNA[J]. Int J Virol,2017,24(4):239-242.(in Chinese)邹红霞，王金环，崔海玲，等．乙型肝炎异常血清学诊断模式与HBV-DNA载量的相关性研究[J]．国际病毒学杂志，2017,24(4):239-242.

[35] LU B,ZHANG B,WANG L,et al. Hepatitis B virus e antigen regulates monocyte function and promotes B lymphocyte activation[J]. Viral Immunol,2017,30(1):35-44.

[36] LEU CM,LU YC,PENG WL,et al. The hepatitis B virus e antigen suppresses the respiratory burst and mobility of human monocytes and neutrophils[J]. Immunobiology,2014,219(11):880-887.

[37] LAN SS,WANG XY,WU LC,et al. Hepatitis B virus e antigen(HBe Ag)may have a negativeeffect on dendrtic cells[J]. Int J Clin Exp Pathol,2016,9(2):742-749.

[38] UNCHWANIWALA N,SHERER NM,LOEB DD. Hepatitis B virus polymerase localizes to the mitochondria,and its terminal protein domain contains the mitochondrial targeting signal[J].J Virol,2016,90(19):8705-8719.

[39] CHOI YM,LEE SY,KIM BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression[J]. World J Gastroenterol,2018,24(16):1708-1724.

[40] WANG H,GUO ZG. Study on HBV pre-C region A1896 gene mutation and clinical drug[J]. J Changchun Univ Chin Med,2019,35(1):144-146.(in Chinese)王涵，郭志钢．HBV前C区A1896基因突变的探讨及临床用药研究[J]．长春中医药大学学报，2019,35(1):144-146.

[41] NISHITSUJI H,HARADA K,UJINO S,et al. Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses[J]. Cancer Sci,2018,109(1):241-249.

[42] RAHMANI Z,HUH KW,LASHER R,et al. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel,HVDAC3,and alters its transmembrane potential[J]. J Virol,2000,74(6):2840-2846.

[43] LI J,HE J,FU Y,et al. Hepatitis B virus X protein inhibits apoptosis by modulating endoplasmic reticulum stress response[J]. Oncotarget,2017,8(56):96027-96034.

[44] CASCIANO JC,BOUCHARD MJ. Hepatitis B virus X protein modulates cytosolic Ca2+signaling in primary human hepatocytes[J]. Virus Res,2018,246:23-27.

[45] GAO Y,FENG J,YANG G,et al. Hepatitis B virus X proteinelevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis[J]. Hepatology,2017,66(5):1413-1429.

施引文献

资源附件(0)

访问统计